نتائج البحث - "Jarque, Isidro"

الوصف: Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant (auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth description of humoral and cell-mediated immune (CMI) responses by age (protocol-defined) or underlying disease (post-hoc) as well as efficacy by underlying disease (post-hoc) of the adjuvanted recombinant zoster vaccine (RZV) in a randomized observer-blind phase III trial (ZOE-HSCT, NCT01610414). 1846 adult auHSCT recipients were randomized to receive a first dose of either RZV or placebo 50-70 days post-auHSCT, followed by the second dose at 1-2 months (M) later. In cohorts of 114-1721 participants, at 1 M post-second vaccine dose: Anti-gE antibody geometric mean concentrations (GMCs) and median gE-specific CD4[2+] T-cell frequencies (CD4 T cells expressing ≥2 of four assessed activation markers) were similar between 18-49 and ≥50-year-olds. Despite lower anti-gE antibody GMCs in non-Hodgkin B-cell lymphoma (NHBCL) patients, CD4[2+] T-cell frequencies were similar between NHBCL and other underlying diseases. The proportion of polyfunctional CD4 T cells increased over time, accounting for 79.6% of gE-specific CD4 T cells at 24 M post-dose two. Vaccine efficacy against HZ ranged between 42.5% and 82.5% across underlying diseases and was statistically significant in NHBCL and multiple myeloma patients. In conclusion, two RZV doses administered early post-auHSCT induced robust, persistent, and polyfunctional gE-specific immune responses. Efficacy against HZ was also high in NHBCL patients despite the lower humoral response.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/3n27k9dmTest

View record in eScholarship

4

دورية أكاديمية

Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus ...

المؤلفون: González-López, Tomás José, Bárez, Abelardo, Bernardo-Gutiérrez, Ángel, Bernat, Silvia, Fernández-Fuertes, Fernando, de Castro, José María Guinea, Jiménez-Bárcenas, Reyes, Jarque, Isidro

مصطلحات موضوعية: Medicine, Cell Biology, Molecular Biology, Pharmacology, Biotechnology, Environmental Sciences not elsewhere classified, Ecology, FOS Biological sciences, Immunology, FOS Clinical medicine, Hematology

الوصف: Immune thrombocytopenia (ITP) is a common autoimmune hematological disorder. Despite this, diagnosis is still challenging due to clinical heterogeneity and the lack of a specific diagnostic test. New findings in the pathology and the availability of new drugs have led to the development of different guidelines worldwide. In the present study, the Delphi methodology has been used to get a consensus on the management of adult patients with ITP in Spain and to help in decision-making. The Delphi questionnaire has been designed by a scientific ad hoc committee and has been divided into 13 topics, with a total of 127 items, covering the maximum possible scenarios for the management of ITP. As a result of the study, a total consensus of 81% has been reached. It is concluded that this Delphi consensus provides practical recommendations on topics related to diagnosis and management of ITP patients to help doctors to improve outcomes. Some aspects remain unclear, without consensus among the experts. Thus, more ...

العلاقة: https://dx.doi.org/10.6084/m9.figshare.25817189Test; https://dx.doi.org/10.1080/09537104.2024.2336104Test

الإتاحة: https://doi.org/10.6084/m9.figshare.25817189.v110.6084/m9.figshare.2581718910.1080/09537104.2024.2336104Test
https://tandf.figshare.com/articles/journal_contribution/Real-life_clinical_practice_in_Spain_in_the_setting_of_new_drug_availability_for_ITP_treatment_A_Delphi-based_Spanish_expert_panel_consensus/25817189/1Test

View record in BASE

5

دورية أكاديمية

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

المؤلفون: Encinas, Cristina, Hernández Rivas, José Ángel, Oriol, Albert, Rosiñol, Laura, Blanchard, María Jesús, Bellon, José María, Garcia Sanz, Ramón, Rubia, Javier de la, López Guía, Ana de la, Jiménez Ubieto, Ana, Jarque, Isidro, Iñigo, Belén, Dourdil, Victoria, Arriba, Felipe de, Cuéllar Pérez-Ávila, Clara, González, Yolanda, Hernández, Miguel Teodoro, Bargay, Joan, Granell, Miguel, Rodríguez Otero, Paula, Silvent, Maialen, Cabrera, Carmen, Rios, Rafael, Alegre, Adrián, Gironella, M., González, M. S., Sureda, A., Sampol, A., Ocio, E. M., Krsnik, I., Garcia, A., García Mateo, A., Soler, J. A., Martin, J., Arguiñano, J. M., Mateos, M. V., Blade, J., San Miguel, J. F., Lahuerta, J. J., Martinez Lopez, Joaquin, GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group

المصدر: Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

مصطلحات موضوعية: Mieloma múltiple, Antibiòtics, Multiple myeloma, Antibiotics

وصف الملف: 8 p.; application/pdf

العلاقة: Reproducció del document publicat a: https://doi.org/10.1038/s41408-022-00652-2Test; Blood Cancer Journal, 2022, vol. 12, num. 4, p. 68; https://doi.org/10.1038/s41408-022-00652-2Test; http://hdl.handle.net/2445/207647Test; 9308998

الإتاحة: https://doi.org/10.1038/s41408-022-00652-2Test
http://hdl.handle.net/2445/207647Test

View record in BASE

النص الكامل

6

دورية أكاديمية

Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study

المؤلفون: de la Rubia, Javier, González, Bernardo, Cruz-Jentoft, Alfonso J., Iglesias, Lorena, Pérez Persona, Ernesto, Gironella Mesa, Mercedes, Jarque, Isidro

المساهمون: Institut Català de la Salut, de la Rubia J, Jarque I Hematology Department, H.U. i Politècnic La Fe. Valencia, Spain. School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain. Centro de Investigación Biomédica en Red de Cáncer, CIBERONC CB16/12/00284, Instituto de Salud Carlos III. Madrid, Spain. González B Hematology Department, H.U. de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain. Cruz-Jentoft AJ Geriatric Unit, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain. Iglesias L Hematology Department, C.H.U. A Coruña. A Coruña, Spain. Persona EP Hematology Department H. U, Vitoria-Gasteiz, Álava, Spain. Gironella M Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Persones grans, Sang - Malalties - Diagnòstic, Medicaments - Toxicologia, DISEASES::Neoplasms::Neoplasms by Site::Hematologic Neoplasms, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Geriatric Assessment, PUBLIC HEALTH::Environmental Health::Science::Toxicology::Toxicity, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias hematológicas, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::evaluación geriátrica, SALUD PÚBLICA::salud ambiental::ciencia::toxicología::toxicidad

الوصف: Chemotherapy; Geriatric assessment; Toxicity ; Quimioterapia; Evaluación geriátrica; Toxicidad ; Quimioteràpia; Avaluació geriàtrica; Toxicitat ; Introduction The GAH (Geriatric Assessment in Hematology) scale is a psychometrically valid tool aimed at identifying older patients with hematological malignancies at higher risk of treatment-related toxicity. Our objective in this study was to determine the weights for each dimension of the GAH scale and the cut-off point to reliably predict treatment tolerability in this population, estimated by a weighted receiver operating characteristic (ROC) analysis and quantified by the area under the curve (AUC). Material and Methods The RETROGAH was a retrospective cohort study including 126 patients who had previously participated in the GAH study. Patients were ≥ 65 years old with newly diagnosed myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), multiple myeloma (MM), or chronic lymphoid leukemia (CLL) and treated with standard front-line therapy within three months after having completed the GAH scale. Results The optimal cut-off value of the GAH total score to discriminate patients at higher risk of treatment toxicity was 42, with 68.5% sensitivity and 55.8% specificity. Using this value, 66.1% of patients evaluated were found to develop some type of toxicity. The AUC was 0.6259 (95% CI: 0.512–0.739; p = 0.035). Discussion The GAH scale not only would enable clinicians to individualize therapy based on individual risk of toxicity but also discriminate patients that will benefit most from intensive treatments from those requiring an adapted approach. While futures studies in clinical practice may improve the model and overcome its limitations, the GAH scale should not be used alone when making treatment decisions. ; This study was supported by Celgene España S.L.

وصف الملف: application/pdf

العلاقة: Journal of Geriatric Oncology;14(1); https://doi.org/10.1016/j.jgo.2022.10.016Test; de la Rubia J, González B, Cruz-Jentoft AJ, Iglesias L, Jarque I, Persona EP, et al. Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study. J Geriatr Oncol. 2023 Jan;14(1):101401.; https://hdl.handle.net/11351/9326Test; 000946209600001

الإتاحة: https://doi.org/10.1016/j.jgo.2022.10.016Test
https://hdl.handle.net/11351/9326Test

View record in BASE

7

دورية أكاديمية

Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing ; Trombocitopenia grave asociada a enfermedad hepática crónica en España: Resultados de un estudio retrospectivo utilizando aprendizaje automático y procesamiento de lenguaje natural

المؤلفون: Calleja-Panero, Jose Luis, Jarque, Isidro, Pérez Romero-Gómez, Manuel, Savana Research Group, García Labrador, Lucia, esteban, rafael

المساهمون: Institut Català de la Salut, Calleja-Panero JL Department of Hepatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. Esteban Mur R Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Jarque I Department of Hematology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. Romero-Gómez M Department of Hepatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain. Savana Research Group Medsavana and Savana Research S.L., Madrid, Spain. García Labrador L Shionogi S.L.U., Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Fetge - Càncer, Trombocitopènia, Aprenentatge automàtic, Tractament del llenguatge natural (Informàtica), INFORMATION SCIENCE::Information Science::Computing Methodologies::Algorithms::Artificial Intelligence::Natural Language Processing, PHENOMENA AND PROCESSES::Mathematical Concepts::Algorithms::Artificial Intelligence::Machine Learning, DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Platelet Disorders::Thrombocytopenia, DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms::Carcinoma, Hepatocellular, CIENCIA DE LA INFORMACIÓN::Ciencias de la información::metodologías computacionales::algoritmos::inteligencia artificial::procesamiento del lenguaje natural, FENÓMENOS Y PROCESOS::conceptos matemáticos::algoritmos::inteligencia artificial::aprendizaje automático, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos de las plaquetas sanguíneas::trombocitopenia, ENFERMEDADES::neoplasias::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas::carcinoma hepatocelular

الوصف: Machine learning; Electronic health records; Chronic liver disease ; Aprendizaje automático; Historias clínicas electrónicas; Hepatopatía crónica ; Aprenentatge automàtic; Històries clíniques electròniques; Hepatopatia crònica ; Background Patients with chronic liver disease (CLD) often develop thrombocytopenia (TCP) as a complication. Severe TCP (platelet count < 50 × 109/L) can increase morbidity and complicate CLD management, increasing bleeding risk during invasive procedures. Objectives To describe the real-world scenario of CLD-associated severe TCP patients’ clinical characteristics. To evaluate the association between invasive procedures, prophylactic treatments, and bleeding events in this group of patients. To describe their need of medical resource use in Spain. Methods This is a retrospective, multicenter study including patients who had confirmed diagnosis of CLD and severe TCP in four hospitals within the Spanish National Healthcare Network from January 2014 to December 2018. We analyzed the free-text information from Electronic Health Records (EHRs) of patients using Natural Language Processing (NLP), machine learning techniques, and SNOMED-CT terminology. Demographics, comorbidities, analytical parameters and characteristics of CLD were extracted at baseline and need for invasive procedures, prophylactic treatments, bleeding events and medical resources used in the follow up period. Frequency tables were generated for categorical variables, whereas continuous variables were described in summary tables as mean (SD) and median (Q1–Q3). Results Out of 1,765,675 patients, 1787 had CLD and severe TCP; 65.2% were male with a mean age of 54.7 years old. Cirrhosis was detected in 46% (n = 820) of patients and 9.1% (n = 163) had hepatocellular carcinoma. Invasive procedures were needed in 85.6% of patients during the follow up period. Patients undergoing procedures compared to those patients without invasive procedures presented higher rates of bleeding events (33% vs 8%, p < 0.0001) and higher ...

وصف الملف: application/pdf

العلاقة: Gastroenterología y Hepatología;47(3); https://doi.org/10.1016/j.gastrohep.2023.05.010Test; Calleja-Panero JL, Esteban Mur R, Jarque I, Romero-Gómez M, Savana Research Group, García Labrador L, et al. Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing. Gastroenterol Hepatol. 2024 Mar;47(3):236–45.; https://hdl.handle.net/11351/11169Test

الإتاحة: https://doi.org/10.1016/j.gastrohep.2023.05.010Test
https://hdl.handle.net/11351/11169Test

View record in BASE

8

دورية أكاديمية

Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

المؤلفون: Mingot-Castellano, María Eva, Canaro, Mariana, Sánchez-González, Blanca, Álvarez-Román, María Teresa, Bárez-García, Abelardo, Bernardo-Gutiérrez, Ángel, Bernat-Pablo, Silvia, Bolaños-Calderón, Estefanía, Butta, Nora, Caballero-Navarro, Gonzalo, Caparrós-Miranda, Isabel Socorro, Entrena-Ureña, Laura, Fernández-Fuertes, Luis Fernando, García-Frade, Luis Javier, Gómez del Castillo Solano, María del Carmen, González-López, Tomás José, Grande-García, Carlos, Guinea de Castro, José María, Jarque, Isidro, Jiménez-Bárcenas, Reyes, López-Ansoar, Elsa, Martínez-Carballeira, Daniel, Martínez-Robles, Violeta, Monteagudo-Montesinos, Emilio, Páramo-Fernández, José Antonio, Perera-Álvarez, María del Mar, Soto-Ortega, Inmaculada, Valcárcel, David, Pascual-Izquierdo, Cristina, Spanish Immune Thrombocytopenia Group (GEPTI), Group of Immune Thrombocytopenia of the Spanish Society of Paediatric Haematology Oncology (SEHOP)

مصطلحات موضوعية: Primary immune thrombocytopenia, Glucocorticoids, Intravenous immunoglobulins, Fostamatinib, Rituximab, Recommendations

الوصف: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0Test/). ; Primary immune thrombocytopenia (ITP) is a complex autoimmune disease whose hallmark is a deregulation of cellular and humoral immunity leading to increased destruction and reduced production of platelets. The heterogeneity of presentation and clinical course hampers personalized approaches for diagnosis and management. In 2021, the Spanish ITP Group (GEPTI) of the Spanish Society of Hematology and Hemotherapy (SEHH) updated a consensus document that had been launched in 2011. The updated guidelines have been the reference for the diagnosis and management of primary ITP in Spain ever since. Nevertheless, the emergence of new tools and strategies makes it advisable to review them again. For this reason, we have updated the main recommendations appropriately. Our aim is to provide a practical tool to facilitate the integral management of all aspects of primary ITP management. ; Peer reviewed

وصف الملف: application/pdf

العلاقة: Publisher's version; The underlying dataset has been published as supplementary material of the article in the publisher platform at https://doi.org/10.3390/jcm12206422Test; https://doi.org/10.3390/jcm12206422Test; Sí; Journal of Clinical Medicine 12(20): 6422 (2023); http://hdl.handle.net/10261/353856Test

الإتاحة: https://doi.org/10.3390/jcm12206422Test
http://hdl.handle.net/10261/353856Test

View record in BASE

النص الكامل